secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elicio Therapeutics, Inc. (ELTX)
CIK:        0001601485
Form:       8-K
Filed at:   2024-01-17T23:59:59+00:00
Accession:  0001601485-24-000009
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elicio presents ELI-002 7P Phase 1/2 trial design at ASCO GI; Phase 1A complete, Phase 2 enrolling
--------------------------------------------------------------------------------

- Phase 1A completed with no dose-limiting toxicities; Phase 2 randomized 2:1 study enrolling PDAC patients.
- ELI-002 7P targets seven KRAS mutations driving 25% of solid tumors using AMP lymph node-targeting platform.
- First patient dosed in randomized Phase 2 cohort comparing ELI-002 7P to standard of care (observation).
- Previous 2-peptide formulation published in Nature Medicine showed tumor biomarker reduction and reduced risk of relapse/death.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601485/000160148524000009/0001601485-24-000009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601485/000160148524000009/angn-20240117.htm
  HTML page:      https://secwatch.observer/filing/0001601485-24-000009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer